Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase

Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection

(2014) Karen D. Sims et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients

(2013) A. H. Talal et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection

(2013) Gregory T. Everson et al.   GASTROENTEROLOGY

1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL

(2013) M. Manns et al.   JOURNAL OF HEPATOLOGY

451 EVALUATION OF PHARMACOKINETIC DRUG–DRUG INTERACTION (DDI) BETWEEN BMS-791325, AN NS5B NON-NUCLEOTIDE POLYMERASE INHIBITOR, DACLATASVIR AND ASUNAPREVIR IN TRIPLE COMBINATION IN HCV GENOTYPE 1-INFECTED PATIENTS

(2013) X. Wang et al.   JOURNAL OF HEPATOLOGY

1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL

(2013) I. Jacobson et al.   JOURNAL OF HEPATOLOGY

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

(2013)   JOURNAL OF HEPATOLOGY

Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C

(2013) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

(2013) Eric Lawitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

(2012) Fiona McPhee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir

(2012) Lenore A. Pelosi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

1194 CHARACTERIZATION OF VIRAL ESCAPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH BMS-791325 AND PEGYLATED INTERFERON-ALFA AND RIBAVIRIN

(2012) D. McPhee et al.   JOURNAL OF HEPATOLOGY

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin

(2012) Dominique Larrey et al.   JOURNAL OF HEPATOLOGY

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus Genotype 1 Infection, But With Issues Still Pending

(2011) Jean–Michel Pawlotsky   GASTROENTEROLOGY

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

(2011) Marc G. Ghany et al.   HEPATOLOGY

Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase

(2011) Michael J. Sofia et al.   JOURNAL OF MEDICINAL CHEMISTRY

Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

(2010) R. A. Fridell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ligand-induced changes in hepatitis C virus NS5B polymerase structure

(2010) Karen Rigat et al.   ANTIVIRAL RESEARCH

Further Insights into the Roles of GTP and the C Terminus of the Hepatitis C Virus Polymerase in the Initiation of RNA Synthesis

(2010) Déborah Harrus et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus

(2010) Michael J. Sofia et al.   JOURNAL OF MEDICINAL CHEMISTRY

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009)

(2009) Marie-Pierre de Béthune   ANTIVIRAL RESEARCH

Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection

(2009) Pierre L Beaulieu   EXPERT OPINION ON THERAPEUTIC PATENTS

Structural Basis for Resistance of the Genotype 2b Hepatitis C Virus NS5B Polymerase to Site A Non-Nucleoside Inhibitors

(2009) Edwin H. Rydberg et al.   JOURNAL OF MOLECULAR BIOLOGY

Identification of Hepatitis C Virus NS5A Inhibitors

(2009) J. A. Lemm et al.   JOURNAL OF VIROLOGY

The global burden of hepatitis C

(2009) Daniel Lavanchy   LIVER INTERNATIONAL

Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors

(2008) K. J. Herlihy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

(2008) A. Y. M. Howe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity In Vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus

(2008) Norman M. Kneteman et al.   HEPATOLOGY

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY

A Locking Mechanism Regulates RNA Synthesis and Host Protein Interaction by the Hepatitis C Virus Polymerase

(2008) Sreedhar Chinnaswamy et al.   JOURNAL OF BIOLOGICAL CHEMISTRY